Section: Contact Information
First Name: Jennifer
Last Name: Agrusa
Institution: Baylor College of Medicine
Address 1: 1102 Bates St
Address 2: Ste 1200
City: Houston
State/Province/Region: TX
Country: US
Zip/Postal Code: 77030
Phone Number: 832-824-4678
Alternate Phone Number:
Email Address: jeagrusa@txch.org

Section: Project Requirements and Description
Group: Requirements to submit AOI
A comprehensive review of previously published data has been completed. : Yes
The specific aims are clear and focused. : Yes
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : Yes
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : Yes
Project Title: Predicting Pulmonary Late Effects in Childhood Cancer Survivors
Planned research population (eligibility criteria):

Original and extended CCSS cohort with primary diagnosis of Hodgkin Lymphoma. Eligibility criteria is as noted below, with the number of respondents to the LTFU 2007 questionnaire provided by Yan Chen (Table 1).

SA2 (telomere length): All subjects must have viably frozen lymphocytes available for analysis. The groups analyzed will include the following:
Cases: HL survivors exposed to either bleomycin and/or chest irradiation and answering in the affirmative to both LTFU 2007 questions H3 and H6 (event occurring at least 5 years off therapy)
Control Group 1: Matched HL survivors answering in the negative to all questions related to pulmonary function

SA3 (biomarkers): All subjects must have buccal DNA available for analysis. The groups analyzed will include the following:
Cases: HL survivors exposed to either bleomycin and/or chest irradiation and answering in the affirmative to both LTFU 2007 questions H3 and H6 (event occurring at least 5 years off therapy)
Control Group 1: Matched HL survivors answering in the negative to all questions related to pulmonary function
Control Group 2: Matched healthy sibling controls

Matching variables for Cases and Control Group 1 (SA2 and SA3) will include the following:
  - Gender
  - Age (±10 years)
  - Bleomycin exposure
  - Radiation dose/fields
  - Time from diagnosis (±10 years)
  - Bone marrow transplant yes/no

Matching variables for Cases and Control Group 2 (SA3) will include:
  - Gender
  - Age (±10 years)

Proposed specific aims:

To characterize the relationship between telomere length, serum biomarkers, therapeutic exposures, and clinical pulmonary dysfunction in HL survivors enrolled in the CCSS by:

1. Determining the relationship between therapy exposures (radiation dose and fields/bleomycin dose) and clinical pulmonary dysfunction, as defined by reports of oxygen requirement AND pulmonary fibrosis from the 2007 Long Term Follow Up Questionnaire.

2. Determining if off therapy telomere length, measured by telomere flow FISH, predicts pulmonary symptoms.

3. Determining if a customized pulmonary fibrosis panel of serum biomarkers are associated with incidence of pulmonary fibrosis or other reported pulmonary diseases.

HYPOTHESIS
Short telomeres, among other serum biomarkers, may be associated with clinical pulmonary disease and predict survivors at risk for pulmonary dysfunction.

Will the project require non-CCSS funding to complete?: Yes

If yes, what would be the anticipated source(s) and timeline(s) for securing funding?:

Sufficient unrestricted funds are available to complete this project, allocated to fellow research mentor, M. Monica Gramatges, MD, PhD. However, we also anticipate submitting this project for an early career/fellowship award both internally and from a private foundation.

Group: Does this project require contact of CCSS study subjects for:
Additional self-reported information: Yes
Biological samples: Yes
Medical record data: Yes
If yes to any of the above, please briefly describe.

Exploratory variables: The following information will be requested from CCSS Medical Records Abstraction Form (MRAF) or questionnaire data:
- Primary cancer diagnosis: only Hodgkin lymphoma survivors
- Chronic health conditions: respiratory, all grades
- Age at primary cancer diagnosis
- Age at diagnosis of chronic health conditions
- Age at most current questionnaire completion
- Current and past medications
- Ever smoked: yes/no
- Currently insured: yes/no
- Date of death (and cause)
- Gender
- Race/ethnicity
- Treatment history, including:
  - Radiation field and dose to prescribed radiation field
  - Chemotherapy bleomycin: cumulative dose
  - Surgery thoracic: yes/no
- 2007 LTFU questionnaire responses to H1-H7 (pulmonary outcomes)

Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)
- Second Malignancy: Secondary
- Chronic Disease: Secondary
- Psychology / Neuropsychology:
- Genetics: Primary
- Cancer Control:
- Epidemiology / Biostatistics: Secondary

Section: Outcomes or Correlative Factors
- Late mortality: Secondary
- Second Malignancy:

Group: Health Behaviors
- Tobacco: Correlative Factors
- Alcohol:
- Physical activity:
- Medical screening:
- Other:
- If other, please specify:

Group: Psychosocial
Insurance:
Marriage:
Education:
Employment:
Other:
If other, please specify:

**Group: Medical Conditions**
Hearing/Vision/Speech:
Hormonal systems:
Heart and vascular:
Respiratory: *Primary*
Digestive:
Surgical procedures:
Brain and nervous system:
Other:
If other, please specify:

**Group: Medications**
Describe medications:

**Group: Psychologic/Quality of Life**
BSI-18:
SF-36:
CCSS-NCQ:
PTS:
PTG:
Other:
If other, please specify:

**Group: Other**
Pregnancy and offspring:
Family history: *Correlative Factors*
Chronic conditions (CTCAE v3): *Primary*
Health status:

**Group: Demographic**
Age: *Correlative Factors*
Race: *Correlative Factors*
Sex: *Correlative Factors*
Other:
If other, please specify:

**Group: Cancer treatment**
Chemotherapy: Correlative Factors
Radiation therapy: Correlative Factors
Surgery: Correlative Factors

**Section: Anticipated Sources of Statistical Support**

CCSS Statistical Center: Yes
Local institutional statistician:
If local, please provide the name(s) and contact information of the statistician(s) to be involved.

Will this project utilize CCSS biologic samples? : Yes
If yes, which of the following? : Buccal cell DNA, Peripheral blood
If other, please explain: Biologic samples requested include both viably frozen lymphocytes (SA2) and DNA (SA3).

**Section: Other General Comments**

Other General Comments: